Lilly outlines $91B-$92B 2026 revenue outlook as Medicare GLP-1 Bridge and Foundayo rollout expand access (NYSE:LLY)
· seekingalpha.com
Eli Lilly Q3 2026 earnings: raised guidance, obesity drug growth, Bridge program momentum, and one-time risks.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...